Stifel on Regenxbio Inc. (RGNX): 'Positive Functional Update at MDA Bolsters “Best-in-Class” Thesis Ahead of Ph.3 DMD Readout'
Tweet Send to a Friend
Stifel analyst Annabel Samimy reiterated a Buy rating and $42.00 price target on Regenxbio Inc. (NASDAQ: RGNX).The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
